Annexon Bioscience's Series B Round

Annexon Bioscience raised a round of funding on June 23, 2016.

Annexon Bioscience is developing a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain, as occurs in Alzheimer's dis…

Articles about Annexon Bioscience's Series B Round: